Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Edoardo Caronna

Edoardo Caronna

Institutions of which they are part

Postdoctoral researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Edoardo Caronna

Edoardo Caronna

Edoardo Caronna

Institutions of which they are part

Postdoctoral researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

Fenotipado molecular de pacientes con migrañA según edad y Sexo a través de la cuanTificación de CGRP en saliva para realizar medicina de precisión: estudio FAST.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI22/01501
Duration: 01/01/2023 - 31/12/2025

Cefaleas y síndromes post-traumatismo craneoencefálico

IP: Patricia Pozo Rosich
Collaborators: Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM20/00217
Duration: 01/01/2021 - 31/12/2022

AhEAD: Algoritmo de predicción de Eficacia de respuesta A tratamiento preventivo en pacientes con migraña crónica: marcaDores biológicos y clínicos

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI19/01684
Duration: 01/01/2020 - 30/06/2024

Related news

Equip del grup de Cefalea i Dolor Neurològic del VHIR

Early initiation of specific treatment for migraine improves the course of the disease

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

Pacient d'un assaig clínic a la consulta

VHIR exceeds 700 active clinical trials to achieve new therapies for patients

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Patricia Pozo

A trial demostrates the efficacy of an oral drug for the prevention of chronic migraine

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

See more

Related professionals

Yaiza García Sánchez

Yaiza García Sánchez

Research technician
Reconstructive Surgery of the Locomotor System
Read more
Belén Monzonis Fortuño

Belén Monzonis Fortuño

Infectious Diseases
Read more
Cristopher Alan Mazo Torre

Cristopher Alan Mazo Torre

Postdoctoral researcher
Clinical Research/Innovation in Pneumonia & Sepsis (CRIPS)
Read more
Patricia Bogdanov Baruj

Patricia Bogdanov Baruj

Postdoctoral researcher
Diabetes and Metabolism
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.